Compare Hershey Co (HSY) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Nuwellis Inc — how do they compare? Hershey Co trades at $162.47 (market cap $32.66B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Hershey Co is far larger — about 14845.5× Nuwellis Inc's market cap, and Hershey Co pays a 3.57% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Nuwellis Inc for 26 Days on average.
| HSY | NUWE | |
|---|---|---|
Market Cap | $32.66B | $2.20M |
Volume | 1,578,237 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $146.65 |
52-Week Low | $157.61 | $0.68 |
Typical Hold Time | 135 Days | 26 Days |
Enterprise Value | $37.79B | -$1.52M |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $161.88, up 0.96% with a bearish technical outlook. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though Q3 2026 earnings are pending. Recent news highlights brand investments and dividend resumption after a near 2-year freeze. Valuation metrics include P/E of 22.2 and P/S of 2.72, with analyst consensus price target at $204.62 representing 26% upside potential.
HSY presents a mixed investment case with strong fundamentals offset by near-term headwinds. The opportunity lies in consistent dividend growth potential and market leadership, while risks include commodity cost pressures and competitive challenges. Analyst sentiment leans cautious with 66% hold ratings, suggesting patience for earnings catalysts and margin stabilization.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
